Zerit licence restricted

HIV virus
HIV virus

Zerit (stavudine) is now indicated for use in patients with HIV infection only when other antiretrovirals cannot be used and then only for the shortest time possible with a switch to alternative therapy as soon as appropriate.

The SPC for the nucleoside reverse transcriptase inhibitor states that given the severe side effects associated with stavudine therapy, including lactic acidosis, lipoatrophy and polyneuropathy, a benefit-risk assessment should be conducted for each patient and use of an alternative antiretroviral carefully considered.

View Zerit drug record

Further information: Bristol-Myers Squibb

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Free resources on MIMS Learning keep you updated on COVID-19

Free resources on MIMS Learning keep you updated on COVID-19

MIMS Learning has a range of free resources for healthcare...

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

First oral GLP-1 agonist launched for type II diabetes

First oral GLP-1 agonist launched for type II diabetes

Prescribers can now consider a GLP-1 agonist as an...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...